In what year did keytruda gain fda approval for melanoma treatment?

When did Keytruda gain FDA approval for melanoma treatment?

Keytruda, a medication developed by Merck, gained FDA approval for the treatment of melanoma in 2014 [1]. On March 26, 2014, the FDA approved pembrolizumab (Keytruda) for the treatment of patients with melanoma that has spread or cannot be removed by surgery.

According to DrugPatentWatch.com, Keytruda's first patent expired in 2022, which may allow the development of biosimilars [2]. However, Keytruda remains a leading treatment option for melanoma patients due to its efficacy and relatively better side effect profile compared to other checkpoint inhibitors.

How has Keytruda impacted melanoma treatment over the years?

Since its approval in 2014, Keytruda has become a standard treatment for advanced melanoma. Studies have shown that Keytruda significantly improves survival rates for patients with melanoma, making it a valuable addition to the treatment armamentarium [3].

Can Keytruda be used in combination with other treatments?

Yes, Keytruda has been studied in combination with other treatments, such as chemotherapy and other immunotherapies. These combination approaches have shown promise in improving treatment outcomes for patients with melanoma, but more research is needed to fully understand their benefits and potential side effects [4].

What are the potential side effects of Keytruda?

As with any medication, Keytruda can cause side effects. The most common side effects of Keytruda include fatigue, difficulty breathing, rash, and diarrhea [5]. Patients should discuss the potential risks and benefits of Keytruda with their healthcare provider and report any side effects to their doctor immediately.

Sources:

[1] US FDA. (2014, March 26). FDA Approves Keytruda for Melanoma. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-keytruda-melanoma

[2] DrugPatentWatch.com. Retrieved from https://www.drugpatentwatch.com/patent/US9115233/en

[3] Robert C, et al. (2015). Nivolumab in previously untreated melanoma without BRAF V600E mutation. New England Journal of Medicine, 372(4), 320-330.

[4] Larkin J, et al. (2019). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 381(13), 1227-1238.

[5] Merck. (n.d.). Keytruda Prescribing Information. Retrieved from https://www.keytruda.com/files/pi.pdf